Navigation Links
Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002

PLYMOUTH, Mich., May 2, 2011 /PRNewswire/ -- Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.  In the Phase 1 study, treatment with ETC-1002 was shown to be safe and well tolerated and to significantly reduce LDL-C levels in subjects with mild dyslipidemia.

ETC-1002, the company's lead product candidate, is a novel small molecule that has demonstrated preclinical and clinical activity as a metabolic regulator of imbalances in lipid and carbohydrate metabolism.  It is being developed to treat dyslipidemia and other cardio-metabolic risk factors.  Mechanistic studies indicate that treatment with ETC-1002 increases AMP-kinase phosphorylation, inhibits fatty acid and cholesterol synthesis and also enhances fatty acid oxidation.   In the Phase 1 study, treatment with ETC-1002 resulted in consistent, dose-related reductions in LDL-C.  The randomized, double-blind, placebo-controlled study included 32 subjects treated with daily doses of ETC-1002 up to 120 mg or placebo for 14 days and 21 subjects treated with 120 mg of ETC-1002 or placebo for 28 days.

"Cardio-metabolic diseases remain the number one cause of death in people around the world, and research indicates that an effective agent to manage both plasma lipids and glucose could offer significant benefit to millions of patients.  The results of our Phase 1 study show a statistically significant lowering of LDL-C in mildly dyslipidemic subjects and a favorable safety profile, and serve as a solid foundation for clinical evaluation in patients with other cardio-metabolic abnormalities," said Roger Newton, PhD, President and CEO of Esperion.

In addition to the results of the Phase 1 study, results from four separate preclinical studies for ETC-1002 were also presented at ATVB this week.  In an oral presentation, results from a study of hyperlipidemic hamsters showed that ETC-1002 was able to lower proatherogenic lipoproteins in plasma, reduce adiposity, decrease body weight gain and improve hepatic steatosis.  ETC-1002 was also shown to improve plasma lipid profiles, hepatic triglyceride content and glycemic control in a KKAy mouse model of diabetes.  Of key importance, these favorable changes resulted in the inhibition of aortic lipid deposition in a LDL receptor-deficient mouse model of atherosclerosis.

"These preclinical studies provide significant additional support for continuing efforts to develop ETC-1002.  A Phase 2 lipid study for ETC-1002 is underway while an additional Phase 2 study to assess the effects of ETC-1002 on glucose control will begin soon.  We are aggressively working to advance this promising therapy to late stage clinical research," Dr. Newton added.

About Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company intends to commercialize innovative, first-in-class therapies focused on promoting cardio-metabolic health. For more information please visit

Media Contact
Agnes Cao
Berry & Company Public Relations

SOURCE Esperion Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
2. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
3. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Samplify Systems Announces Availability of Prism FP Floating Point Compression
6. Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
8. BioMarin Announces First Quarter 2011 Financial Results
9. IRIDEX Announces First Quarter 2011 Conference Call and Release Date
10. Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
11. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Post Your Comments:
(Date:11/27/2015)... , Nov. 26, 2015 ... addition of the "2016 Global Tumor ... Country Volume and Sales Segment Forecasts, Innovative ... report to their offering. --> ... of the "2016 Global Tumor Marker ...
(Date:11/26/2015)... , 26 november 2015 AAIPharma ... de geplande investering aan van ten minste ... laboratoria en het mondiale hoofdkantoor in ... zal resulteren in extra kantoorruimte en extra ... de groeiende behoeften van de farmaceutische en ...
(Date:11/26/2015)... -- --> --> Juntendo ... optimal contrast weighting of MRI for patients with Multiple ... research agreement with SyntheticMR in order to use SyMRI in ... possible to generate multiple contrast images from a single scan ... thus making it possible to both fine tune images and ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the health care in America. As people age, more care is needed, especially ... are rising, and medical professionals are being overworked. The forgotten part of this ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Health-E-minds, an innovative online platform for mental health and wellness consultation, has collaborated ... This partnership will bridge the knowledge gap experienced by parents and bring advice ...
Breaking Medicine News(10 mins):